Nat Mater:揭秘癌细胞扩散转移核心机制,相关药物研发也步入正轨

2019-10-30 Paris 转化医学网

癌细胞的扩散和转移是癌症患者高复发率和高死亡率的主要原因,也是科学家们攻克癌症的关键。

癌细胞的扩散和转移是癌症患者高复发率和高死亡率的主要原因,也是科学家们攻克癌症的关键。近日,《Nature Materials》和 《PLOS Computational Biology》两大国际刊同时发表文章揭秘癌细胞利用周围阻止扩散的关键机制,不仅如此,对抑制该过程的药物的探索也有了突破,相关文章以“Extracellular matrix anisotropy is determined by TFAP2C-dependent regulation of cell collisions”为题在线发表。

众所周知,体内的所有组织都含有维持其结构的蛋白质支架,这种脚手架会随着年龄的增长而退化,导致细胞衰老等迹象。而狡猾的癌细胞却恰好利用这一点,破坏支架的形状,形成一种组织结构通路,进一步通过该通路转移到周围的组织。

然而,尽管我们了解到这些通路与癌症的进展有关,但对控制这些组织结构形成的机制却知之甚少。基于现有研究,他们了解到,细胞外基质(ECM)是一种能够维持组织结构的纤维蛋白和蛋白聚糖支架,在癌细胞扩散通路的构成中起关键作用,而ECM 沉积和维持的主要介质是成纤维细胞。成纤维细胞是结缔组织中最多的细胞类型,能够分泌ECM成分从而形成组织结构框架,早在1971年,科学家就描述了静止的成纤维细胞在组织重构中被活化后变成MF,在肿瘤组织中被称为CAF。

在本次研究中,研究人员将长期成像,计算建模,转录组学分析,短干扰 RNA(siRNA)和基于信息学的药理学筛选,以鉴定成纤维细胞和 ECM 比对的分子调节剂。通过这些方法,他们确定了成纤维细胞的集体行为--细胞碰撞指导。进一步探索发现,转录因子 TFAP2C 部分地通过控制 RND3 的表达来调节细胞碰撞的指导。

ECM各向异性指示癌细胞迁移并实现力的全局协调

如同众多生物活动过程,都需要依靠蛋白质间的相互作用,而蛋白质之间的“分子开关”保证了各类特定活动的运转。癌细胞也不例外。RND3 定位于细胞间碰撞区域,在该区域下调放线菌素活性。如果没有适当的机制,单元碰撞引导将失败,从而导致各向同性的矩阵生成,即细胞扩散。综上来看,TFap2C蛋白在该过程中占据核心位置,不出意外,通过识别控制这些碰撞的蛋白质(TFap2C),研究人员便可以寻找出能抑制这种蛋白质的药物,进而阻断这些通路的形成和癌细胞的扩散。果然,利用现有的数据集和实验,该研究成功地确定了五种影响组织中通路形成的药物。

该研究为攻克癌症带来了广阔的前景,当然,目前只是一个充满希望的初步成果,理论还需实践的检验,下一步还需要进行动物实验来证实并检验该方法的安全性。

原始出处:Danielle Park, Esther Wershof, Stefan Boeing, et al. Extracellular matrix anisotropy is determined by TFAP2C-dependent regulation of cell collisions. Nat Mater (2019) 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1745959, encodeId=af321e4595953, content=<a href='/topic/show?id=191ee15256b' target=_blank style='color:#2F92EE;'>#癌细胞扩散#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71525, encryptionId=191ee15256b, topicName=癌细胞扩散)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9c735637129, createdName=yb6572, createdTime=Tue Sep 01 22:59:00 CST 2020, time=2020-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883953, encodeId=c2b718839538f, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Mar 31 01:59:00 CST 2020, time=2020-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907390, encodeId=77de190e39063, content=<a href='/topic/show?id=ff9a62090ce' target=_blank style='color:#2F92EE;'>#核心机制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62090, encryptionId=ff9a62090ce, topicName=核心机制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f65b226, createdName=circumcision, createdTime=Mon Dec 02 13:59:00 CST 2019, time=2019-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252652, encodeId=043a12526524e, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Thu Oct 31 15:59:00 CST 2019, time=2019-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300325, encodeId=6ef41300325eb, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Thu Oct 31 15:59:00 CST 2019, time=2019-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301479, encodeId=268d13014e947, content=<a href='/topic/show?id=aa308e8307e' target=_blank style='color:#2F92EE;'>#药物研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87830, encryptionId=aa308e8307e, topicName=药物研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Thu Oct 31 15:59:00 CST 2019, time=2019-10-31, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1745959, encodeId=af321e4595953, content=<a href='/topic/show?id=191ee15256b' target=_blank style='color:#2F92EE;'>#癌细胞扩散#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71525, encryptionId=191ee15256b, topicName=癌细胞扩散)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9c735637129, createdName=yb6572, createdTime=Tue Sep 01 22:59:00 CST 2020, time=2020-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883953, encodeId=c2b718839538f, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Mar 31 01:59:00 CST 2020, time=2020-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907390, encodeId=77de190e39063, content=<a href='/topic/show?id=ff9a62090ce' target=_blank style='color:#2F92EE;'>#核心机制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62090, encryptionId=ff9a62090ce, topicName=核心机制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f65b226, createdName=circumcision, createdTime=Mon Dec 02 13:59:00 CST 2019, time=2019-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252652, encodeId=043a12526524e, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Thu Oct 31 15:59:00 CST 2019, time=2019-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300325, encodeId=6ef41300325eb, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Thu Oct 31 15:59:00 CST 2019, time=2019-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301479, encodeId=268d13014e947, content=<a href='/topic/show?id=aa308e8307e' target=_blank style='color:#2F92EE;'>#药物研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87830, encryptionId=aa308e8307e, topicName=药物研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Thu Oct 31 15:59:00 CST 2019, time=2019-10-31, status=1, ipAttribution=)]
    2020-03-31 liye789132251
  3. [GetPortalCommentsPageByObjectIdResponse(id=1745959, encodeId=af321e4595953, content=<a href='/topic/show?id=191ee15256b' target=_blank style='color:#2F92EE;'>#癌细胞扩散#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71525, encryptionId=191ee15256b, topicName=癌细胞扩散)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9c735637129, createdName=yb6572, createdTime=Tue Sep 01 22:59:00 CST 2020, time=2020-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883953, encodeId=c2b718839538f, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Mar 31 01:59:00 CST 2020, time=2020-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907390, encodeId=77de190e39063, content=<a href='/topic/show?id=ff9a62090ce' target=_blank style='color:#2F92EE;'>#核心机制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62090, encryptionId=ff9a62090ce, topicName=核心机制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f65b226, createdName=circumcision, createdTime=Mon Dec 02 13:59:00 CST 2019, time=2019-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252652, encodeId=043a12526524e, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Thu Oct 31 15:59:00 CST 2019, time=2019-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300325, encodeId=6ef41300325eb, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Thu Oct 31 15:59:00 CST 2019, time=2019-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301479, encodeId=268d13014e947, content=<a href='/topic/show?id=aa308e8307e' target=_blank style='color:#2F92EE;'>#药物研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87830, encryptionId=aa308e8307e, topicName=药物研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Thu Oct 31 15:59:00 CST 2019, time=2019-10-31, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1745959, encodeId=af321e4595953, content=<a href='/topic/show?id=191ee15256b' target=_blank style='color:#2F92EE;'>#癌细胞扩散#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71525, encryptionId=191ee15256b, topicName=癌细胞扩散)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9c735637129, createdName=yb6572, createdTime=Tue Sep 01 22:59:00 CST 2020, time=2020-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883953, encodeId=c2b718839538f, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Mar 31 01:59:00 CST 2020, time=2020-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907390, encodeId=77de190e39063, content=<a href='/topic/show?id=ff9a62090ce' target=_blank style='color:#2F92EE;'>#核心机制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62090, encryptionId=ff9a62090ce, topicName=核心机制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f65b226, createdName=circumcision, createdTime=Mon Dec 02 13:59:00 CST 2019, time=2019-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252652, encodeId=043a12526524e, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Thu Oct 31 15:59:00 CST 2019, time=2019-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300325, encodeId=6ef41300325eb, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Thu Oct 31 15:59:00 CST 2019, time=2019-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301479, encodeId=268d13014e947, content=<a href='/topic/show?id=aa308e8307e' target=_blank style='color:#2F92EE;'>#药物研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87830, encryptionId=aa308e8307e, topicName=药物研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Thu Oct 31 15:59:00 CST 2019, time=2019-10-31, status=1, ipAttribution=)]
    2019-10-31 yxch36
  5. [GetPortalCommentsPageByObjectIdResponse(id=1745959, encodeId=af321e4595953, content=<a href='/topic/show?id=191ee15256b' target=_blank style='color:#2F92EE;'>#癌细胞扩散#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71525, encryptionId=191ee15256b, topicName=癌细胞扩散)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9c735637129, createdName=yb6572, createdTime=Tue Sep 01 22:59:00 CST 2020, time=2020-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883953, encodeId=c2b718839538f, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Mar 31 01:59:00 CST 2020, time=2020-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907390, encodeId=77de190e39063, content=<a href='/topic/show?id=ff9a62090ce' target=_blank style='color:#2F92EE;'>#核心机制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62090, encryptionId=ff9a62090ce, topicName=核心机制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f65b226, createdName=circumcision, createdTime=Mon Dec 02 13:59:00 CST 2019, time=2019-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252652, encodeId=043a12526524e, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Thu Oct 31 15:59:00 CST 2019, time=2019-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300325, encodeId=6ef41300325eb, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Thu Oct 31 15:59:00 CST 2019, time=2019-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301479, encodeId=268d13014e947, content=<a href='/topic/show?id=aa308e8307e' target=_blank style='color:#2F92EE;'>#药物研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87830, encryptionId=aa308e8307e, topicName=药物研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Thu Oct 31 15:59:00 CST 2019, time=2019-10-31, status=1, ipAttribution=)]
    2019-10-31 lqvr
  6. [GetPortalCommentsPageByObjectIdResponse(id=1745959, encodeId=af321e4595953, content=<a href='/topic/show?id=191ee15256b' target=_blank style='color:#2F92EE;'>#癌细胞扩散#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71525, encryptionId=191ee15256b, topicName=癌细胞扩散)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9c735637129, createdName=yb6572, createdTime=Tue Sep 01 22:59:00 CST 2020, time=2020-09-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883953, encodeId=c2b718839538f, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Mar 31 01:59:00 CST 2020, time=2020-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907390, encodeId=77de190e39063, content=<a href='/topic/show?id=ff9a62090ce' target=_blank style='color:#2F92EE;'>#核心机制#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62090, encryptionId=ff9a62090ce, topicName=核心机制)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f65b226, createdName=circumcision, createdTime=Mon Dec 02 13:59:00 CST 2019, time=2019-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252652, encodeId=043a12526524e, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Thu Oct 31 15:59:00 CST 2019, time=2019-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1300325, encodeId=6ef41300325eb, content=<a href='/topic/show?id=ed5ee332423' target=_blank style='color:#2F92EE;'>#研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73324, encryptionId=ed5ee332423, topicName=研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aea0290, createdName=lqvr, createdTime=Thu Oct 31 15:59:00 CST 2019, time=2019-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1301479, encodeId=268d13014e947, content=<a href='/topic/show?id=aa308e8307e' target=_blank style='color:#2F92EE;'>#药物研发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87830, encryptionId=aa308e8307e, topicName=药物研发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a435298, createdName=huirong, createdTime=Thu Oct 31 15:59:00 CST 2019, time=2019-10-31, status=1, ipAttribution=)]

相关资讯

Nature:仁济医院“更聪明”肝癌治疗策略 先让癌细胞衰老再给予精准清除

​先诱导癌细胞衰老,再给予其致命精准重击,且不伤及正常细胞。今天,《自然》杂志在线发表上海交通大学医学院附属仁济医院上海市肿瘤研究所与荷兰癌症研究所一项“更聪明”肝癌治疗的合作研究成果,为肝癌精准治疗提供了新思路。

Nat Immunol:地毯式搜索、精准辨认,免疫新疗法让所有癌细胞无所遁形!

近日,来自耶鲁大学的陈斯迪团队研发了一种基于CRISPR基因表达调控的集成内源基因激活免疫疗法 (MAEGI, Multiplex Activation of Endogenous Genes as Immunotherapy),绝杀之前的癌症免疫疗法,可对所有癌细胞进行地毯式搜索,辨认伪装癌细胞,最终进行免疫清除。这并不是纸上谈兵,该疗法已然在三阴性乳腺癌、黑色素瘤和胰腺癌等三种小鼠肿瘤模型中取

Cell Metab:癌细胞中转硫途径的调控,转硫途径是半胱氨酸匮乏时维持细胞生长的关键

1924年,德国生物学家奥托·瓦伯格(Otto Warburg)首次发现肿瘤细胞无论在低氧和氧气充足的环境中,都倾向于通过一种低效的利用葡萄糖产生乳酸的糖酵解方式供给能量,从而促进增殖,此发现被称为Warburg效应,也被定义为肿瘤的七大特征之一。此后,越来越多的研究发现肿瘤的发生和发展伴随着诸多细胞代谢方式的改变。与正常细胞代谢相比,肿瘤细胞代谢的基本方式是在营养匮乏的微环境中通过劫持、重塑多种

Nat Commun:催眠大师重现江湖,乳腺癌药物开启癌细胞的睡眠模式

伦敦帝国理工学院的科学家发现,乳腺癌药物会迫使一些癌细胞进入“睡眠模式”,这为找到使癌细胞永久沉睡的方法开辟了新的道路。

JCI:科学家给癌症患者制定 “食疗” 菜谱

美国科学家在多种癌细胞中发现了一个代谢弱点,而这些细胞具有一个共同的特征,即被称为剪接体的细胞机器发生了一种基因突变。

Nat Immunol:耶鲁科学家开发全新的癌症免疫疗法

免疫疗法已经彻底改变了癌症的治疗,但是现有的疗法并不适用于所有患者,而且对某些癌症根本不起作用。因为它有时无法识别癌细胞的所有分子伪装,因此大大降低了治疗效果。 北京时间10月15日,发表在《Nature Immunology》上的一项新研究中,美国耶鲁大学的研究团队开发的一种新系统可以让癌细胞无处遁形,以帮助免疫系统发现并消灭其他形式的免疫疗法无法识别的肿瘤。 为了解决现有疗法无法识别癌细胞